Skip to main content

Table 2 Treatment-emergent adverse events

From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

 

n (%)

Total patients

9 (13.2%)

Injection-site reactions

2 (2.9%)

Constipation

5 (7.4%)

Blood pressure elevation (20 mmHg <)

1 (1.5%)

Alopecia

1 (1.5%)

Diarrhea

1 (1.5%)